ALPX News
Archived Headlines
- US IPO Week Ahead: Gene editing biotech plots the first $100+ million IPO of the 4Q 10/14/22
- US IPO Week Ahead: Quiet October continues with trickle of small deals 10/07/22
- US IPO Week Ahead: The IPO calendar returns to small deals 09/16/22
- Infectious disease biotech Alopexx revises terms ahead of $15 million IPO 09/07/22
- Infectious disease biotech Alopexx sets terms for $15 million IPO 08/24/22
See more
Infectious disease biotech Alopexx nearly triples offering size ahead of $33 million IPO
Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, raised the proposed deal size for its upcoming IPO on Friday. The Cambridge, MA-based company now plans to raise $33 million by offering 3 million shares at ...read more
Nano-cap biotech Alopexx cuts shares offered by 20% ahead of $12 million
Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, lowered the proposed deal size for its upcoming IPO on Monday. The Cambridge, MA-based company now plans to raise $12 million by offering 2.4 million shares ...read more
US IPO Week Ahead: More micro-caps after a big week for IPOs
After the busiest week for $100+ million IPOs in over a year, six small companies are currently scheduled to go public in the week ahead, four of which are eligible for inclusion in our IPO stats. Electric bike maker SONDORS (SODR) plans to raise $20 million ...read more
US IPO Week Ahead: No deals scheduled for the first week of November
There are no confirmed IPOs scheduled for the week ahead, though a few micro-caps are on the calendar looking to price on a "day-to-day" basis. A number of IPOs have refreshed their filings in recent weeks, mostly micro-caps, however this past week's strong...read more